These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17456829)

  • 21. Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model.
    Mazzaccara C; Conti V; Liguori R; Simeon V; Toriello M; Severini A; Perricone C; Meccariello A; Meccariello P; Vitale DF; Filippelli A; Sacchetti L
    PLoS One; 2013; 8(8):e71505. PubMed ID: 23990957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy.
    Gong IY; Tirona RG; Schwarz UI; Crown N; Dresser GK; Larue S; Langlois N; Lazo-Langner A; Zou G; Roden DM; Stein CM; Rodger M; Carrier M; Forgie M; Wells PS; Kim RB
    Blood; 2011 Sep; 118(11):3163-71. PubMed ID: 21725053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients.
    Yoshizawa M; Hayashi H; Tashiro Y; Sakawa S; Moriwaki H; Akimoto T; Doi O; Kimura M; Kawarasaki Y; Inoue K; Itoh K
    Thromb Res; 2009 Jun; 124(2):161-6. PubMed ID: 19135231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
    Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
    Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics of warfarin dose requirements in Hispanics.
    Cavallari LH; Momary KM; Patel SR; Shapiro NL; Nutescu E; Viana MA
    Blood Cells Mol Dis; 2011 Feb; 46(2):147-50. PubMed ID: 21185752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.
    Kuanprasert S; Dettrairat S; Palacajornsuk P; Kunachiwa W; Phrommintikul A
    J Med Assoc Thai; 2009 Dec; 92(12):1597-601. PubMed ID: 20043560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
    Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
    Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
    Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
    Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose].
    Huang SW; Xiang DK; Wu HL; Chen BL; An BQ; Li GF
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):661-5. PubMed ID: 22161100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
    Wen MS; Lee M; Chen JJ; Chuang HP; Lu LS; Chen CH; Lee TH; Kuo CT; Sun FM; Chang YJ; Kuan PL; Chen YF; Charng MJ; Ray CY; Wu JY; Chen YT
    Clin Pharmacol Ther; 2008 Jul; 84(1):83-9. PubMed ID: 18183038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of warfarin dose: why, when and how?
    Eriksson N; Wadelius M
    Pharmacogenomics; 2012 Mar; 13(4):429-40. PubMed ID: 22379999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
    Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.